Longeveron is presenting at three longevity investment meetings in October while advancing laromestrocel (Lomecel-B), an investigational mesenchymal stem cell therapy not approved by the FDA. A medRxiv preprint describes a post hoc exploratory analysis of the 49-participant Phase 2a CLEAR MIND study suggesting reduced brain neuroinflammation in Alzheimer's disease, and Phase 2b data published in Cell Stem Cell reported improved physical condition in patients with age-related frailty after nine months.
Key Points
- Post hoc Phase 2a analysis suggests reduced Alzheimer's neuroinflammation; preprint unreviewed
- Phase 2b intravenous therapy improved physical condition in age-related frailty
- XPRIZE Healthspan Milestone 2 award provided $1 million for future trial
Longevity Analysis
Cell-based therapy targeting inflammation sits at the intersection of two of the most consequential drivers of late-life decline: immune dysregulation in the brain and the loss of functional capacity that defines clinical frailty. The same intervention being evaluated for cognitive and physical endpoints reflects a shift toward treating the shared inflammatory substrate rather than isolated diagnoses. Interpretation requires discipline — exploratory post hoc signals in 49 participants and a preprint awaiting peer review establish direction, not proof, and the regulatory status remains investigational.
Original published by Longevity.Technology.